Novo Nordisk and biosimilar developer Alvotech are both contending with renewed regulatory pressure over manufacturing practices at facilities with troubled inspection histories. The U.S. Food and Drug Administration this week disclosed concerns
More
As the 2026 election cycle advances, state attorney general races are emerging as a critical factor in how companies assess their legal and regulatory exposure across the country. Once considered niche political
More
The 2026 election cycle spans 30 states, two U.S. territories, and the District of Columbia (33 attorney general offices total), featuring an unprecedented volume of structural changes driven by constitutional term limits
More
The Department of Justice is drawing renewed criticism over its Biglaw subpoena strategy, with observers widely sceptical the approach will achieve its intended outcome. Legal commentators have suggested the DOJ’s handling of
More
Global technology stocks suffered a severe sell-off on Friday, with chip manufacturers bearing the brunt of a sweeping downturn that rattled markets from Tokyo to New York. The Nasdaq Composite plunged 1.9
More
IBM (NYSE: IBM) shares dropped sharply by 25% after the company issued a warning related to its second quarter outlook on AI spending. The significant share price decline reflects growing investor concern
More
The FTSE 250 index has long played second fiddle to its larger counterpart, but income investors are increasingly turning their attention to its dividend potential. While the FTSE 100 dominates headlines, the
More
Outgoing Prime Minister Sir Keir Starmer collected sport-related freebies worth tens of thousands of pounds during his two years in Downing Street. Official figures declared in the register of accepted gifts and
More
Novartis has secured traditional FDA approval for Fabhalta, also known as iptacopan, to slow kidney function decline in adults with primary immunoglobulin A nephropathy. The approval targets adults with IgAN who are
More
Germany’s sweeping health insurance overhaul is colliding with a US Section 301 trade investigation, creating mounting pressure across global pharmaceutical supply chains. A fixed 15.5% manufacturer rebate on patented branded drugs has
More